

IFW

Docket No. CEN 5008 CIP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on

JUNE 17, 2004 (Date of Deposit)

KIRK BAUMEISTER
(Name of applicant, assignee, or Registered Representat

JUNE 17, 2004

(Date of Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: LEE ET AL

Serial No. : 10/727,432 Art Unit:

Filed: DECEMBER 4, 2003 Examiner:

FOR : CLONAL MYELOMA CELL LINES USEFUL FOR MANUFACTURING

PROTEINS IN CHEMICALLY DEFINED MEDIA

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

X In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with \square the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/CEN5008CIP/KB the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

| | Statement in Accordance with §1.97(e) (attached); or |
|-----------------|--|
| | |
| | Please charge Deposit Account No. 10- |
| | 0750/CEN5008CIP/KB the fee of \$180.00 as set |
| | forth in §1.17(p). |
| ☐ In | accordance with §1.97(d), this Information |
| Disclosure St | catement is being filed after the mailing date of |
| either a Fina | al Action under §1.113 or a Notice of Allowance |
| under §1.313 | but before the payment of the Issue Fee. |
| Applicant(s) | hereby petition(s) for consideration of this |
| Information I | Disclosure Statement. Included are: Statement in |
| Accordance w | th §1.97(e) as set forth below and the fee of |
| \$180.00 as se | et forth in §1.17(p). |
| | |
| Co ₁ | pies of each of the references listed on the |
| attached Form | n PTO-1449 are enclosed herewith. |
| 5 7 | in a second line of the obtained Harm DEC |
| _ | pies of references listed on the attached Form PTO |
| 1449 are enc. | losed herewith EXCEPT THAT: |
| | In view of the voluminous nature of references |
| | [list as appropriate], and the likelihood that |
| | these references are available to the Examiner, |
| | copies are not enclosed herewith. |
| | _ |
| \boxtimes | If any of the foregoing publications are not |
| | available to the Examiner, Applicant will |
| | endeavor to supply copies at the Examiner's |
| | request. |
| | |
| The | ere are no listed references which are not in the |
| English langu | lage. |

| The relevance of those listed references which are |
|--|
| not in the English language is as follows: |
| |
| <pre>Attached are copies of search report(s) from</pre> |
| corresponding patent application(s), which are listed on the |
| attached Submission Under MPEP 609 D. |
| |
| Attached are the following non-published pending |
| patent applications which may be deemed relevant, which are |
| listed on the attached Submission Under MPFP 609 D |

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5008CIP/KB. This form is submitted in triplicate.

Respectfully submitted,

KIRK BAUMEISTER Reg. No. 33,833

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610) 240-8465 DATED: JUNE 17, 2004



-222PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

| ond to a collection or information unless it displays a valid OMB control number. | | | | |
|---|------------------|--|--|--|
| Application Number | 10/727,432 | | | |
| Filing Date | December 4, 2003 | | | |
| First Named Inventor | Chi Chang Lee | | | |
| Group Art Unit | | | | |
| Examiner Name | | | | |
| Attorney Docket Number | CEN 5008 CIP | | | |

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code Examiner Cite of Cited Document where relevant passages of Cited Document Initials Number (if known) or relevant figures appear No.1 mm-dd-yyyy 6274335 Goeddel et al 08-14-2001 5723441 Higley et al 03-03-1998 6008195 Selsted 12-28-1999 4780313 Koichiro et al 10-25-1988 4504469 Melin et al 03-12-1985 5199942 Gillis 04-06-1993

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, Foreign Patent Document Date of Publication of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant mm-dd-yyyy T⁶ Applicant of Cited Document figures appear Initials Office³ Number⁴ KindCode⁵ No.1

| Examiner | | | | Date | | | | |
|-----------|------|------|--|------------|------|---|--|--|
| Signature | | | | Considered | | | | |
| | | | | | | - | | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450...

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

| to a concount of fine maner and the control figure of | | | | |
|---|------------------|--|--|--|
| Application Number | 10/727,432 | | | |
| Filing Date | December 4, 2003 | | | |
| First Named Inventor | Chi Chang Lee | | | |
| Group Art Unit | | | | |
| Examiner Name | | | | |
| Attorney Docket Number | CEN 5008 CIP | | | |
| | | | | |

| | | OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | |
|------------|------|---|----------------|
| | | Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item | |
| Examiner's | Cite | (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), | T ² |
| Initials* | No.1 | publisher, city and/or country where published | |
| | | HILL, M., ""Adaptive state of mammalian cells and its nonseparability suggestive of a quantum system," SCRIPTA MEDICA., | |
| | | 2000, PAGES 211-222, Vol. 73, No. 4. | |
| | | FAULDS ET AL, "Abciximab: a review of its pharmacology and therapeutic potential in ischaemic heart disease," DRUGS, | |
| | | 1994, pages 583-598, Vol. 48, No. 4. | |
| | | MOUSER ET AL, "Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease," CLINICAL THERAPEUTICS, 1999, pages 932-942, Vol. 21, No. 6, USA. | |
| | | GORFIEN ET AL, "Growth of NSO cells in protein-free, chemically defined medium," LIFE TECHNOL INC., 2000, pages 682-687, Vol. 16, No. 5, USA. | |
| | | LOUIS ET AL, "Maintenance of clonotypic myeloma cells in serum-free media," BLOOD, 2000, Abstract #4940, Vol. 96, No. 11, USA | |
| | | FRESHNEY, R. IAN, "Culture of Animal Cells," A MANUAL OF BASIC TECHNIQUE, CHAPTER 7, pp. 92-3, UNIVERSITY OF GLASGOW. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Examiner | Date |
|-----------|------------|
| Signature | Considered |
| | |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.